| Bioactivity | GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome[1]. | ||||||||||||
| Target | IC50: 0.6 μM (SARS-CoV PLpro) | ||||||||||||
| Invitro | GRL0617 (0-50 μM; 48 h) exibits significantly antiviral activity in SARS-CoV infected Vero E6 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | GRL0617 | ||||||||||||
| CAS | 1093070-16-6 | ||||||||||||
| Formula | C20H20N2O | ||||||||||||
| Molar Mass | 304.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24. |